# Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation

> clinical trial · VERIFIED · 2026-08-13

Status: RECRUITING · Sponsor: Allist Pharmaceuticals, Inc. · Condition: EGFR

- Company: Allist Pharmaceuticals, Inc.
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06956001

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.